Apr 23, 2019 - Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 23, 2019 - The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Apr 22, 2019 - Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Apr 22, 2019 - The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Mar 29, 2019 - Overpriced toxic stocks are generally susceptible to outside shocks and burdened with a huge amount of debt.
Mar 14, 2019 - Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
Mar 13, 2019 - Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
Mar 13, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and burdened with huge amount of debt.